Cargando…
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder
Major depressive disorder (MDD) is a leading cause of disability worldwide, yet current treatment strategies remain limited in their mechanistic diversity. Recent evidence has highlighted a promising novel pharmaceutical target—the KCNQ-type potassium channel—for the treatment of depressive disorder...
Autores principales: | Tan, Aaron, Costi, Sara, Morris, Laurel S., Van Dam, Nicholas T., Kautz, Marin, Whitton, Alexis E., Friedman, Allyson K., Collins, Katherine A., Ahle, Gabriella, Chadha, Nisha, Do, Brian, Pizzagalli, Diego A., Iosifescu, Dan V., Nestler, Eric J., Han, Ming-Hu, Murrough, James W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494706/ https://www.ncbi.nlm.nih.gov/pubmed/30385872 http://dx.doi.org/10.1038/s41380-018-0283-2 |
Ejemplares similares
-
KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients
por: Millichap, John J., et al.
Publicado: (2016) -
Ezogabine skin discoloration is reversible after discontinuation
por: Mathias, Sally V., et al.
Publicado: (2017) -
Clinical utility, safety, and tolerability of ezogabine (retigabine) in the treatment of epilepsy
por: Ciliberto, Michael A, et al.
Publicado: (2012) -
Migration and Fate Specification in the Ventral Striatum
Publicado: (2005) -
Signatures of Value Comparison in Ventral Striatum Neurons
por: Strait, Caleb E., et al.
Publicado: (2015)